GlassScriptPhysician profile
Andrew P Schwartz
NPI 1295787000
$124,388.68
in general payments reported to CMS, 2019-2025
8 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $6,811 · 2021: $12K · 2022: $26K · 2023: $29K · 2024: $29K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $67K · Food and Beverage: $1,935 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $67,012.92 |
| Food and Beverage | $1,935.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $262.50 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $124,017.42 | 2019-2025 | Veritas Vision System, Tecnis Iol, Tecnis Simplicity |
| Dompe US, INC. | $141.51 | 2025 | Oxervate |
| Alcon Vision LLC | $132.12 | 2022-2025 | Simbrinza, Clareon |
| Bausch & Lomb Americas INC. | $35.68 | 2023 | Miebo |
| Ivantis, INC | $22.39 | 2021 | |
| Sun Pharmaceutical Industries INC. | $13.88 | 2023 | Cequa |
| Amgen INC. | $13.68 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.